Significant Efficacy Results Following 18 Months of Treatment1

TYMLOS significantly reduced the risk of vertebral fractures1

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 18 months1

Proportion of postmenopausal women with vertebral fractures after 18 months treatment with TYMLOS vs placebo

P<0.0001.1
Results reported in the modified intent-to-treat (ITT) population, which included patients who had both pretreatment and posttreatment spine radiographs.1
Primary endpoint.1

7x fewer women on TYMLOS experienced new vertebral fractures at 18 months versus those on placebo1

See nonvertebral fracture data Minus iconPlus icon

TYMLOS significantly reduced the risk of nonvertebral fractures1

Cumulative incidence of nonvertebral fractures* at 19 months (18 months of treatment plus 1 month of follow-up without treatment)1

Nonvertebral fracture risk after 18 months TYMLOS treatment

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

P=0.049.1

P-value based on the log-rank test.1

Results reported in ITT population, which included patients randomized in the efficacy study.1

Secondary endpoint.2

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

P-value based on the log-rank test.1

P=0.049.1

Results reported in ITT population, which included patients randomized in the efficacy study.1

Secondary endpoint.2

See change in BMDMinus iconPlus icon

TYMLOS provided significant increases in BMD1

Nonvertebral fracture risk after 18 months TYMLOS treatment

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 18 months1

Nonvertebral fracture risk after 18  months TYMLOS treatment

P<0.0001.1

Results reported in ITT population, which included patients randomized in the efficacy study;

mean percentage change in BMD was last observation carried forward (LOCF).1

Secondary endpoint3; BMD captured with DXA scans.2

P<0.0001.1

Results reported in ITT population, which included patients randomized in the efficacy study; mean percentage change in BMD was last observation carried forward (LOCF).1

Secondary endpoint3; BMD captured with DXA scans.2

Arrow

View continued efficacy results with TYMLOS followed by alendronate

References: 1. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. A randomized, double-blind, placebo-controlled, comparative phase 3 multicenter study to evaluate the safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk of fracture [supplement 2]. Waltham, MA: Radius Health, Inc; 2015. http://jamanetwork.com/data/Journals/JAMA/935644/JOI160092supp2_prod.pdf. Accessed April 3, 2018. 3. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. [Erratum: JAMA. 2017;317(4):442.]

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.   All rights reserved.    04/18.   TYM-US-01391

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.
All rights reserved. 04/18.
TYM-US-01391

Back to Top